Pirenoxine
Based on 1 Customer Validation
Pirenoxine (Catalin K) is an antioxidant with lens-protective activity. Pirenoxine inhibits lens sclerosis, prevents lipid peroxidation and suppresses lens protein opacification. Pirenoxine blocks benzoquinone acetic acid-induced cataract progression. Pirenoxine can be used in research related to presbyopia and cataracts.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 95.0%
- CAS 番号: 1043-21-6
- 分子式: C16H8N2O5
- 分子量:308.25
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
体外実験
Pirenoxine (PRX) (0.016-0.1 μM; 0-4 days) sodium delays selenite-induced early lens opacification and reduces the degradation of insoluble lens proteins in lens homogenates of SD rat pups[2].
Pirenoxine sodium reduces UVC-induced lens opacity and γ-crystallin degradation in porcine lens homogenates; it delays the onset and reduces the opacity of glucose/galactose-induced diabetic cataracts in intact goat lenses[2].
Pirenoxine sodium (10-4 M) elevates the levels of glutathione (GSH), water-soluble proteins and sulfur-containing amino acids in lenses of galactose-induced diabetic SD rats, while it only produces partial effects at 10-5 M[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
Pirenoxine (concentration 0.005-2%; topical administration; 2 drops, three times daily; for 30 consecutive days) sodium reduces the incidence of cataracts in galactose-induced diabetic cataract SD rats and tryptophan deficiency-induced congenital cataract colored rabbits, and improves the antioxidant/protein-related indicators of their lenses[2].
Pirenoxine (concentration 0.0053%; topical administration; three times daily; for 60 consecutive days) sodium slows disease progression and reverses lens opacification in Wistar rats with established galactose-induced diabetic cataracts[2].
Pirenoxine (0.005% concentration; topical administration; 4 times daily; for 120 consecutive days) sodium delays the progression of age-related cataracts in senescence-accelerated mice[2].
Pirenoxine (2.5-5 mg/kg; subcutaneous injection; single administration) sodium prevents early gross lens opacification in sodium selenite-induced cataract SD young rats only at the dose of 5 mg/kg[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (6-week-old male, tobacco smoke-induced presbyopia model)[1]
-
Dosage:0.005%
-
Administration:eye drops; 4 times daily; 12 days
-
Result:Reduced lens elasticity ratio significantly compared to PBS-treated smoke-exposed rats.
-
Animal Model:Wistar rat[2]
-
Dosage:0.8 mg/15 mL concentration
-
Administration:topical; 3 times daily; 7 days
-
Result:Increased superoxide dismutase (SOD) activity in serum compared to untreated controls.
Increased catalase (CAT) activity in serum compared to untreated controls.
Decreased malondialdehyde (MDA) levels in serum compared to untreated controls.
Increased SOD activity in lens tissue compared to untreated controls.
Increased CAT activity in lens tissue compared to untreated controls.
Increased reduced glutathione (GSH) levels in lens tissue compared to untreated controls.
-
Animal Model:
-
Dosage:0.005% concentration; 0.01% concentration; 2% concentration
-
Administration:topical; 2 drops 3 times daily; 30 days
-
Result:Reduced cataract incidence by 40%.
Increased lens GSH levels.
Increased lens water-soluble protein levels.
Increased lens sulfur-containing amino acid levels.
-
Animal Model:Wistar rat[2]
-
Dosage:0.0053% concentration
-
Administration:topical; 3 times daily; 60 days
-
Result:Reduced lens opacity between days 10 and 90 of galactose exposure.
Reduced progression of lens opacity between days 10 and 90 of galactose exposure.
化学情報
-
CAS 番号 1043-21-6
-
性状 Solid
-
分子量 308.25
-
分子式 C16H8N2O5
-
Color Light brown to brown
-
SMILES
O=C(C1=CC(O)=C2C(C(C=C3OC4=C(N=C32)C=CC=C4)=O)=N1)O
-
別名
Catalin K
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
H2O : < 0.1 mg/mL (insoluble)
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
純度とドキュメンテーション
-
データシート (290 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Tsuneyoshi Y, et al. Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy. Scientific reports. 2017 Jul 28;7(1):6819. [Content Brief]
[2]. Upaphong P, et al. The Possible Positive Mechanisms of Pirenoxine in Cataract Formation. International journal of molecular sciences. 2022 Aug 21;23(16):9431. [Content Brief]
Pirenoxine 関連分類
HY-108296 関連分類
Powered by Bioz